Biotalys NV (BTLS) - Total Liabilities
Based on the latest financial reports, Biotalys NV (BTLS) has total liabilities worth €9.18 Million EUR (≈ $10.73 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biotalys NV - Total Liabilities Trend (2018–2024)
This chart illustrates how Biotalys NV's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Biotalys NV to evaluate short-term liquidity relative to the company's equity base.
Biotalys NV Competitors by Total Liabilities
The table below lists competitors of Biotalys NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MICROPORT CARDIO.MEDTECH.
F:72X
|
Germany | €450.55 Million |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
USA | $17.96 Million |
|
Creades AB Series A
LSE:0QI9
|
UK | Skr39.00 Million |
|
Ching Feng Home Fashions Co Ltd
TW:9935
|
Taiwan | NT$5.77 Billion |
|
Bixolon Co. Ltd
KQ:093190
|
Korea | ₩46.31 Billion |
|
Ensari Deri Gida Sanayi ve Ticaret AS
IS:ENSRI
|
Turkey | TL770.87 Million |
|
MODISON LIMITED
NSE:MODISONLTD
|
India | Rs2.28 Billion |
|
Bhageria Industries Limited
NSE:BHAGERIA
|
India | Rs2.67 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Biotalys NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BTLS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotalys NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotalys NV (2018–2024)
The table below shows the annual total liabilities of Biotalys NV from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.14 Million ≈ $10.69 Million |
-16.99% |
| 2023-12-31 | €11.01 Million ≈ $12.88 Million |
-3.42% |
| 2022-12-31 | €11.40 Million ≈ $13.33 Million |
+0.39% |
| 2021-12-31 | €11.36 Million ≈ $13.28 Million |
+7.02% |
| 2020-12-31 | €10.61 Million ≈ $12.41 Million |
+64.81% |
| 2019-12-31 | €6.44 Million ≈ $7.53 Million |
-25.64% |
| 2018-12-31 | €8.66 Million ≈ $10.12 Million |
-- |
About Biotalys NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6… Read more